se ha leído el artículo
array:24 [ "pii" => "S1578219017302147" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.06.017" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "1662" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2017;108:620-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 935 "formatos" => array:3 [ "EPUB" => 32 "HTML" => 744 "PDF" => 159 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731017301801" "issn" => "00017310" "doi" => "10.1016/j.ad.2016.12.022" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "1662" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2017;108:620-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 979 "formatos" => array:3 [ "EPUB" => 3 "HTML" => 688 "PDF" => 288 ] ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Enfermedades autoinflamatorias en dermatología pediátrica. Parte 2: síndromes histiocítico-macrofágicos y síndromes vasculopáticos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "620" "paginaFinal" => "629" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Autoinflammatory Diseases in Pediatric Dermatology–Part 2: Histiocytic, Macrophage Activation, and Vasculitis Syndromes" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0045" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1085 "Ancho" => 1252 "Tamanyo" => 118235 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S. Hernández-Ostiz, G. Xirotagaros, L. Prieto-Torres, L. Noguera-Morel, A. Torrelo" "autores" => array:5 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Hernández-Ostiz" ] 1 => array:2 [ "nombre" => "G." "apellidos" => "Xirotagaros" ] 2 => array:2 [ "nombre" => "L." "apellidos" => "Prieto-Torres" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Noguera-Morel" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Torrelo" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0045"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219017302147" "doi" => "10.1016/j.adengl.2017.06.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302147?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017301801?idApp=UINPBA000044" "url" => "/00017310/0000010800000007/v2_201708291352/S0001731017301801/v2_201708291352/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219017302123" "issn" => "15782190" "doi" => "10.1016/j.adengl.2016.12.025" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "1589" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2017;108:630-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1143 "formatos" => array:3 [ "EPUB" => 37 "HTML" => 976 "PDF" => 130 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Practical Dermatology</span>" "titulo" => "Diagnostic and Prognostic Relevance of the Cutaneous Manifestations of Neurofibromatosis Type 2" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "630" "paginaFinal" => "636" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Manifestaciones cutáneas de la neurofibromatosis tipo 2: interés diagnóstico y pronóstico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0030" "etiqueta" => "Figure 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 1131 "Ancho" => 850 "Tamanyo" => 104460 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Plaque-type neural proliferation on the anterior face of the wrist of a patient with neurofibromatosis type 2.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Plana-Pla, I. Bielsa-Marsol, C. Carrato-Moñino" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Plana-Pla" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Bielsa-Marsol" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "Carrato-Moñino" ] 3 => array:1 [ "colaborador" => "on Behalf of the Group of <span class="elsevierStyleItalic">Centros, Servicios y Unidades de Referencia (CSUR)</span> in Phakomatosis" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731017300455" "doi" => "10.1016/j.ad.2016.12.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017300455?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302123?idApp=UINPBA000044" "url" => "/15782190/0000010800000007/v2_201708291348/S1578219017302123/v2_201708291348/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219017302111" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.06.015" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "1659" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2017;108:609-19" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1004 "formatos" => array:3 [ "EPUB" => 35 "HTML" => 764 "PDF" => 205 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Autoinflammatory Diseases in Pediatric Dermatology-Part 1: Urticaria-like Syndromes, Pustular Syndromes, and Mucocutaneous Ulceration Syndromes" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "609" "paginaFinal" => "619" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedades autoinflamatorias en dermatología pediátrica. Parte 1: síndromes urticariformes, síndromes pustulosos y síndromes con ulceraciones cutáneo-mucosas" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1020 "Ancho" => 975 "Tamanyo" => 237937 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">DITRA (deficiency of the IL-36 receptor antagonist). Generalized pustular eruption with polycyclic contours on an erythematous base, similar to an outbreak of generalized pustular psoriasis.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S. Hernández-Ostiz, L. Prieto-Torres, G. Xirotagaros, L. Noguera-Morel, Á. Hernández-Martín, A. Torrelo" "autores" => array:6 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Hernández-Ostiz" ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Prieto-Torres" ] 2 => array:2 [ "nombre" => "G." "apellidos" => "Xirotagaros" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Noguera-Morel" ] 4 => array:2 [ "nombre" => "Á." "apellidos" => "Hernández-Martín" ] 5 => array:2 [ "nombre" => "A." "apellidos" => "Torrelo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731017301771" "doi" => "10.1016/j.ad.2016.12.021" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017301771?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302111?idApp=UINPBA000044" "url" => "/15782190/0000010800000007/v2_201708291348/S1578219017302111/v2_201708291348/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Autoinflammatory Diseases in Pediatric Dermatology–Part 2: Histiocytic, Macrophage Activation, and Vasculitis Syndromes" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "620" "paginaFinal" => "629" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "S. Hernández-Ostiz, G. Xirotagaros, L. Prieto-Torres, L. Noguera-Morel, A. Torrelo" "autores" => array:5 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Hernández-Ostiz" ] 1 => array:2 [ "nombre" => "G." "apellidos" => "Xirotagaros" ] 2 => array:2 [ "nombre" => "L." "apellidos" => "Prieto-Torres" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Noguera-Morel" ] 4 => array:4 [ "nombre" => "A." "apellidos" => "Torrelo" "email" => array:1 [ 0 => "atorrelo@aedv.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Niño Jesús, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedades autoinflamatorias en dermatología pediátrica. Parte 2: síndromes histiocítico-macrofágicos y síndromes vasculopáticos" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1333 "Ancho" => 1320 "Tamanyo" => 262650 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Blau syndrome. Erythematous-violaceous nodules in both pretibial areas, with a very similar appearance to erythema nodosum.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Histiocytic and Macrophage Activation Syndromes</span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Blau Syndrome</span><p id="par0005" class="elsevierStylePara elsevierViewall">NOD2-associated pediatric granulomatous arthritis, also known as <span class="elsevierStyleItalic">Blau syndrome</span> or <span class="elsevierStyleItalic">early-onset sarcoidosis</span>, is a hereditary autosomal dominant disorder characterized by mutations in the NACHT domain of <span class="elsevierStyleItalic">NOD2</span> (<span class="elsevierStyleItalic">CARD15</span>). Like NLRP proteins, NOD2 is an intracytoplasmic receptor involved in innate immune responses to bacteria.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">1</span></a> When stimulated, it triggers the formation of granulomatous lesions through the activation of NF-kB. <span class="elsevierStyleItalic">NLRPs and NODs</span> can interact and feed into each other, giving rise to mixed clinical presentations. Many patients without a family history have <span class="elsevierStyleItalic">de novo NOD2</span> mutations and incomplete clinical penetrance. Phenotypic expression is highly variable, even within the same families and in patients with the same mutations. Blau syndrome has a similar phenotype to pediatric granulomatous arthritis, with inflammation affecting the eyes, joints, and skin.</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Cutaneous Manifestations</span><p id="par0010" class="elsevierStylePara elsevierViewall">Skin manifestations are among the main manifestations of Blau syndrome. Beginning in early infancy, patients develop asymptomatic, local or generalized erythematous or brownish papules or papules and nodules (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>) that can present as a lichenoid eruption. The palms and soles may be affected. Other skin manifestations described in NOD2 disorders include ichthyosiform disorders,<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">2</span></a> a form of panniculitis that is very similar to erythema nodosum (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>), and leukocytoclastic vasculitis. The most common cutaneous manifestation, which should raise suspicion of Blau syndrome, is a mild, early-onset generalized eruption of brownish papules that often resolves spontaneously in the first years of life.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">3</span></a> Histopathologic findings are similar to those observed in sarcoidosis, and include noncaseating granulomas with histiocytes, lymphocytes, eosinophils (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>), and giant nucleated cells that are strongly positive when stained with periodic acid-Schiff. Electron microscopy shows so-called <span class="elsevierStyleItalic">comma bodies</span> in epithelioid cells.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">3</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Associated Clinical Manifestations</span><p id="par0015" class="elsevierStylePara elsevierViewall">Characteristic associated clinical manifestations include chronic polyarticular synovitis, symmetric hypertrophic tenosynovitis, and recurrent granulomatous anterior uveitis, although panuveitis is more common. Joint involvement is the most common—and severe—noncutaneous manifestation. It begins before the age of 10 years and affects the hands, wrists, ankles, knees, and elbows. The lesions are painless cysts that grow slowly over time and become considerably swollen, although they do not limit mobility until several decades after onset. Granulomatous inflammatory infiltrates formed by giant multinucleated cells are observed in the synovial membrane. Anterior uveitis can be complicated by involvement of the posterior pole, and patients may also develop cataracts, glaucoma, or loss of vision. Ocular involvement is bilateral in most cases.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">3</span></a> The granulomatous infiltrate can also affect, although less frequently, the liver, the salivary glands, the lungs, the kidneys, the nervous system, and the arteries, causing cranial neuropathy, large vessel arteritis, malignant hypertension, and cerebral infarction. The lymph nodes may also be affected, but unlike in sarcoidosis,<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">4</span></a> the hilar nodes are not affected, and unlike in other chronic autoinflammatory disorders, secondary amyloidosis is very rare.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">5</span></a></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">H Syndrome</span><p id="par0020" class="elsevierStylePara elsevierViewall">H syndrome is caused by mutations in the <span class="elsevierStyleItalic">SLC29A3</span> gene, located on chromosome 10q22. The letter H refers to several hallmark features of the syndrome, such as hyperpigmentation, hypertrichosis, hepatosplenomegaly, hypogonadism, heart anomalies, and hearing loss.</p><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Cutaneous Manifestations</span><p id="par0025" class="elsevierStylePara elsevierViewall">The progressive appearance of hyperpigmented, hypertrichotic plaques (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>) and marked sclerosis on the extremities and abdomen is a highly characteristic finding in H syndrome. The lower half of the body is more frequently affected. In most cases the condition begins with hyperpigmentation on the internal surface of the thighs, which then spreads, but generally sparing the knees and buttocks. Some patients also develop ichthyosiform scaling. Skin biopsy shows hyperpigmentation of the basal layer with acanthosis and hyperplasia, similar to that seen in seborrheic keratosis, together with marked fibrosis of the dermis and subcutaneous tissue; the fibrosis is mild in the papillary dermis and much more intense in the subcutis, where it causes progressive obliteration of the fat lobules (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>). The accompanying infiltrate is mainly composed of numerous, small histiocytes (CD68<span class="elsevierStyleSup">+</span>, S100<span class="elsevierStyleSup">+</span>, CD1a<span class="elsevierStyleSup">−</span>)with clear cytoplasm<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">6</span></a> and occasional emperipolesis. Characteristic electron microscopic findings include a distended endoplasmic reticulum and sparse lysosomes.</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Associated Clinical Manifestations</span><p id="par0030" class="elsevierStylePara elsevierViewall">Associated manifestations in H syndrome include deafness, low stature, flexion contractures, dilated veins in the legs and abdominal wall, heart anomalies, early ischemic cardiomyopathy,<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">7</span></a> hepatosplenomegaly, scrotal masses, hypogonadism, delayed puberty, azoospermia, and hyperglycemia/diabetes mellitus.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">8</span></a></p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome</span><p id="par0035" class="elsevierStylePara elsevierViewall">Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome is the paradigm of proteasome-immunoproteasome dysfunction disorders.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">9</span></a> Proteasomes are complex intracellular protein structures that break down and remove ubiquitinated protein residues that are no longer useful. Proteasome is present as a constitutive subunit in cells, but when catalytic requirements increase (in response to an infection or physical stimulus), it is replaced by an inducible immunoproteasome subunit. Deficient immunoproteasome assembly or loss of function results in a considerable accumulation of ubiquitinated proteins inside macrophages, triggering major cellular stress and an increased production of type I interferon (IFN) due to the secondary activation of the JAK-kinase signaling pathway. The result is a vicious circle characterized by the continuous formation and accumulation of intracellular protein residues. The main features of CANDLE syndrome are recurrent fever, visceral inflammation, lipodystrophy, and fixed cutaneous lesions that do not tend to resolve spontaneously. They appear during the first year of life, typically within the first few weeks. Genetic studies have shown mutations in several genes that code for different proteasome/immunoproteasome subunits, such as β5i, β1i, β7, and α3. The mutations result in decreased catalytic activity of the immunoproteasome or prevent its assembly. Although the most common mutations in patients with CANDLE syndrome are biallelic <span class="elsevierStyleItalic">PSMB8</span> mutations, there have been recent reports of monoallelic mutations with a digenic inheritance<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">10</span></a> in genes that code for different subunits and of <span class="elsevierStyleItalic">POMP</span> mutations in 1 patient (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Cutaneous Manifestations</span><p id="par0040" class="elsevierStylePara elsevierViewall">Cutaneous manifestations of CANDLE syndrome consist of annular edematous, erythematous violaceous plaques with elevated borders that mainly affect the trunk (<a class="elsevierStyleCrossRef" href="#fig0030">Fig. 6</a>), although they can also affect the extremities (mainly the interphalangeal joints) and the area around the mouth and the eyes, causing persistent violaceous erythema.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">11</span></a> Although these lesions resolve spontaneously, leaving hyperpigmentation or residual ecchymotic macules, they recur with sufficient frequency to be considered a chronic, persistent skin disorder. Histopathologic findings include dense perivascular and interstitial inflammatory infiltrates in the dermis, with occasional involvement of the subcutaneous tissue, absence of vasculitis, and presence of karyorrhexis, albeit inconsistently. The infiltrate is composed of atypical mononuclear myeloid cells with large mottled, long or kidney-shaped nuclei and scant eosinophilic cytoplasm,<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">11</span></a> accompanied by a variable number of neutrophils and eosinophils (<a class="elsevierStyleCrossRef" href="#fig0035">Fig. 7</a>). Immunohistochemical studies show positive staining for myeloperoxidase, lysozyme, Mac387, CD68 (KP1), and CD163<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">12,13</span></a> (<a class="elsevierStyleCrossRef" href="#fig0040">Fig. 8</a>) and a double population of myeloid cells and macrophages. Finally, the presence of plasmacytoid CD123<span class="elsevierStyleSup">+</span> dendritic cells, which are powerful producers of type I IFN, indicate that this cytokine has a more than significant role in CANDLE syndrome.</p><elsevierMultimedia ident="fig0030"></elsevierMultimedia><elsevierMultimedia ident="fig0035"></elsevierMultimedia><elsevierMultimedia ident="fig0040"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">Less frequently, patients develop violaceous nodules that leave residual hyperpigmentation, hypertrichosis, acanthosis nigricans, and alopecia areata.<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">14</span></a> Progressive lipodystrophy on the face, upper extremities, and trunk is a highly characteristic, defining feature of CANDLE syndrome.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Associated Clinical Manifestations</span><p id="par0050" class="elsevierStylePara elsevierViewall">According to reports in the literature, all patients experience frequent and sometimes even daily episodes of high fever (> 30<span class="elsevierStyleHsp" style=""></span>°C) and are also affected by low weight and short stature.<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">15</span></a> Associated clinical manifestations include enlarged lymph nodes, hepatosplenomegaly, arthralgia without arthritis, and multiple other inflammatory events, such as chondritis, conjunctivitis, nodular episcleritis, epididymitis, nephritis, otitis, parotiditis, and aseptic meningitis. Patients with CANDLE syndrome may also have dysmorphic features such as a broad nasal bridge, fat lips, and an everted lower lip.<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">15</span></a> Laboratory studies typically show elevated acute phase reactants, chronic anemia, elevated liver enzymes, and transient lymphopenia during flares.</p></span></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Vasculopathy Syndromes</span><p id="par0055" class="elsevierStylePara elsevierViewall">Within the group of vasculopathy syndromes we will discuss interferonopathies and disorders caused by adenosine deaminase 2 (ADA2) deficiency.</p><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Type I Interferonopathies</span><p id="par0060" class="elsevierStylePara elsevierViewall">Type I IFNs are cytokines with a key role in the link between the innate and acquired immune system. Viral DNA, which is recognized by the type 1 IFN receptor, activates STING (stimulator of IFN genes)–dependent signaling to produce IFN and other proinflammatory cytokines.<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">16</span></a> This increased production of IFN stimulates the immunoproteasome, which activates the JAK-STAT pathway with greater frequency, generating even more IFN and intensifying and perpetuating the immune response and autoinflammatory conditions. In this next section we will look at the most relevant interferonopathies in dermatology and describe their hallmark clinical features.</p><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Aicardi-Goutières Syndrome</span><p id="par0065" class="elsevierStylePara elsevierViewall">Aicardi-Goutières syndrome is a genetically highly heterogeneous neurodegenerative disorder with a high degree of consanguinity. It is characterized by cerebral and cutaneous involvement. Although mostly transmitted in an autosomal recessive manner, there have been reports of autosomal dominant transmission. Disease-causing mutations have been detected in 7 genes: <span class="elsevierStyleItalic">TREX1</span>, which codes for a 3′-5′ exonuclease, <span class="elsevierStyleItalic">RNASEH2A</span>, <span class="elsevierStyleItalic">RNASEH2B</span>, <span class="elsevierStyleItalic">RNASEH2C</span>, <span class="elsevierStyleItalic">SAMHD1</span>, <span class="elsevierStyleItalic">IFIH1</span>, and <span class="elsevierStyleItalic">ADAR1</span>.<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">17</span></a> The mutations cause deficient destruction of viral genetic material, which is needed to downregulate the production of IFN in infected cells. This dysregulation of IFN-α generates proinflammatory situations that trigger secondary vasculitic conditions, such as encephalopathy or acrocyanosis. Although Aicardi-Goutières can be congenital, onset is more common in the first year of life in healthy term infants.</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Cutaneous Manifestations</span><p id="par0070" class="elsevierStylePara elsevierViewall">Characteristic cutaneous manifestations include chilblain-like lesions located mainly on the fingers although they can also affect the feet and ears. They are more common in winter and may be accompanied by acral necrosis. Apart from the better-known cutaneous manifestations of Aicardi-Goutières, such as photosensitivity, acrocyanosis, petechial purpura on the upper half of the trunk and face, swelling of the hands and feet, periungual erythema, nail dystrophy, and cold feet, there have been reports of blueberry muffin baby, which mimics the clinical phenotype of a TORCH-type congenital viral infection in the form of red-bluish generalized macules and papules.<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">18</span></a> The histopathologic findings in this last condition are compatible with extramedullary hematopoiesis and include a polymorphous infiltrate in the dermis and the subcutaneous tissue composed predominantly of precursor erythroid and myeloid cells that show positive immunostaining with glycophorin A, myeloperoxidase, peroxidase, CD20, and CD3, confirming, respectively, the presence of erythrocytes, leukocytes, B cells, and T cells.<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">18</span></a></p><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Associated Clinical Manifestations</span><p id="par0075" class="elsevierStylePara elsevierViewall">Patients develop severe subacute encephalopathy that stabilizes after a period of progression and is associated with calcification of the basal ganglia, leukodystrophy, progressive microcephaly, and pyramidal-extrapyramidal dysfunction accompanied by epilepsy and aseptic febrile episodes. There have also been reports of chronic arthroplasty with progressive acral contractures and oral mucosal ulcers.<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">19</span></a> Laboratory studies show high levels of IFN-α, neopterin, biopterin,<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">20</span></a> and lymphocytosis, which is also observed in cerebrospinal fluid (CSF). Elevated IFN-α in CSF is considered a major diagnostic criterion for Aicardi-Goutières syndrome.<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">21</span></a> Patients may also present thrombocytopenia, elevated liver enzymes, and in some cases, hyperpolygammaglobulinemia, and Coombs-positive hemolytic anemia. All these conditions have a highly variable clinical expression and none of them are necessary for diagnosis.<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">19</span></a></p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Familial Chilblain Lupus</span><p id="par0080" class="elsevierStylePara elsevierViewall">Familial chilblain lupus is a rare familial form of cold-induced cutaneous lupus erythematosus that may be sporadic, or less frequently, hereditary. It is generally caused by a mutation in <span class="elsevierStyleItalic">TREX1</span>. <span class="elsevierStyleItalic">TREX1</span> is the major intracellular repair exonuclease and its deficiency leads to the accumulation of nucleic acids and the activation of the innate immune system accompanied by an increase in INF that favors the development of autoimmunity.<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">6</span></a></p></span></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Cutaneous Manifestations</span><p id="par0085" class="elsevierStylePara elsevierViewall">Starting from an early age, children develop violaceous perniotic plaques at acral sites that may ulcerate and are clinically and histologically very similar to lesions seen in Aicardi<span class="elsevierStyleItalic">-</span>Goutières syndrome. Histology shows interface dermatitis with basal cell vacuolization accompanied by a dense perivascular lymphohistiocytic inflammatory infiltrate in the dermis, together with mucin in the reticular dermis. Direct immunofluorescence (DIF) shows basal deposits of immunoglobulin (Ig) M, IgA, and C3 and perivascular deposits of C3 and fibrinogen.<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">22,23</span></a></p><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Associated Clinical Manifestations</span><p id="par0090" class="elsevierStylePara elsevierViewall">Patients occasionally develop systemic manifestations such as arthralgia and nonerosive arthritis. Laboratory studies show mild pancytopenia, hypergammaglobulinemia, rheumatoid factor, antinuclear antibodies (ANAs), and anti-Ro/SSA antibodies.<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">23</span></a> Cryoglobulins and cold agglutinins are negative. Up to 20% of patients develop systemic lupus erythematosus (SLE)<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">24</span></a> and there is a lack of consensus on the association with anorexia.</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">STING-associated Vasculopathy With Onset in Infancy</span><p id="par0095" class="elsevierStylePara elsevierViewall">As previously explained, sensing of viral RNA and DNA is the main biological trigger for the activation of STING, which is a transmembrane protein located in the endoplasmic reticulum that induces the production of IFN. STING-associated vasculopathy with onset in childhood is due to gain-of-function mutations in <span class="elsevierStyleItalic">STING</span>.<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">25,26</span></a> The protein is widely expressed in endothelial and alveolar cells. STING hyperfunction causes inflammation in endothelial cells, generating vaso-occlusive phenomena and pulmonary lesions, possibly due to the activation of macrophages or alveolar pneumocytes. The release of IFN triggers a positive feedback loop, as it directly triggers the transcription of other proinflammatory cytokines and activates JAK-kinases, which, in turn trigger the phosphorylation and dimerization of STAT1/STAT2, which initiate the transcription of <span class="elsevierStyleItalic">IFN</span> genes.</p></span></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Cutaneous Manifestations</span><p id="par0100" class="elsevierStylePara elsevierViewall">The clinical manifestations begin in the first year of life as a telangiectatic pustular and/or bullous rash located at acral sites and on the cheek. This eruption then progresses, mostly in response to exposure to cold, to acral violaceous nodules and plaques that become necrotic in most cases and can affect extensive areas, causing significant tissue loss. Characteristic findings are capillary tortuosity of the nail bed, and telangiectasias on the nose, cheeks, extremities, and hard palate. Other possible manifestations are perforation of the nasal septum, dystrophic nails, resorption of the distal phalanges, and digital gangrene requiring amputation.<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">26</span></a> Histopathologic findings include a dense, predominantly neutrophilic inflammatory infiltrate in the dermis with leukocytoclastic vasculitis and thrombotic microangiopathy of the small dermal vessels,<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">26</span></a> some of which may contain deposits of IgM, C3, and fibrin.</p><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Associated Clinical Manifestations</span><p id="par0105" class="elsevierStylePara elsevierViewall">Patients with STING-associated vasculopathy with onset in infancy have recurrent episodes of low-grade fever and may also experience delayed growth, severe lung disease with enlarged hilar or paratracheal lymph nodes, interstitial fibrosis, and emphysematous changes caused by a lymphocytic inflammatory infiltrate.<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">27</span></a> The laboratory study shows increased erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and on occasions, ANA, cytoplasmic antineutrophil cytoplasmic antibodies, and antiphospholipid antibodies, which tend to normalize with time.</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">C1q Deficiency</span><p id="par0110" class="elsevierStylePara elsevierViewall">C1q is a protein that forms part of the C1 complex of the complement system. In addition to its role in activating the complement cascade, it inhibits the production of IFN by plasmacytoid dendritic cells and peripheral blood mononuclear cells. Loss-of-function <span class="elsevierStyleItalic">C1q</span> mutations result in a phenotype similar to that seen in SLE in 90% of cases.<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">28</span></a></p></span></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Cutaneous Manifestations</span><p id="par0115" class="elsevierStylePara elsevierViewall">The cutaneous manifestations of C1q deficiency include butterfly rash on the face, discoid lupus–type lesions, and Raynaud phenomenon, similar to that seen in SLE.<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">29</span></a></p><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Associated Clinical Manifestations</span><p id="par0120" class="elsevierStylePara elsevierViewall">Extracutaneous manifestations of C1q deficiency include segmental mesangial glomerulonephritis (which differs from the typical nephritis seen in SLE), neurological symptoms, and serious recurrent infections caused by deficient functioning of the classic complement pathway. Plasma levels of CH50 and C1q are practically inexistent, contrasting with C2, C4, and C1 inhibitor levels, which are normal or elevated. ANAs, rheumatoid factor, and anti-Smith antibodies are positive. Biopsy of lesions shows basal layer vacuolization, while DIF shows deposits of IgG, IgM, IgA, and C3. The clinical similarities with SLE combined with the presence of clinical features of immunodeficiency are highly suggestive of complement factor deficiency.</p></span></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">ADA2 Deficiency</span><p id="par0125" class="elsevierStylePara elsevierViewall">ADA2 deficiency is associated with nonspecific clinical manifestations that overlap with features of polyarteritis nodosa, with necrotizing vasculopathy of the small and medium vessels and livedo reticularis. There is a strong familial predisposition and the condition has accordingly also been called <span class="elsevierStyleItalic">familial polyarteritis nodosa</span>. Low blood levels of ADA2 have been linked to endothelial alterations and greater activation of macrophages, situations that probably cause vasculitis and cerebrovascular accidents.<a class="elsevierStyleCrossRefs" href="#bib0395"><span class="elsevierStyleSup">30,31</span></a> The clinical manifestations are highly variable, even in families carrying the same mutations, particularly in terms of age of onset, organs affected, and severity of organ involvement.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">32</span></a></p><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Cutaneous Manifestations</span><p id="par0130" class="elsevierStylePara elsevierViewall">Typical clinical manifestations of ADA2 deficiency include changes associated with poor arterial flow, such as livedo reticularis, Raynaud phenomenon, ischemia, and digital necrosis. Biopsy of lesions shows periarteritis, fibrinoid necrosis, and destruction of the elastic lamina of the cutaneous arterioles. There may also be leukocytoclastic vasculitis and panniculitis.</p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Associated Clinical Manifestations</span><p id="par0135" class="elsevierStylePara elsevierViewall">Additional manifestations include febrile episodes and frequent aneurysms in the renal, mesenteric, and coronary arteries. Ischemia can cause renal, gastrointestinal, genital, musculoskeletal, cardiovascular, and neurologic manifestations. Of particular note are renal hypertension and a high risk of cerebral ictus during childhood.<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">31</span></a></p></span></span></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Management of Autoinflammatory Syndromes</span><p id="par0140" class="elsevierStylePara elsevierViewall">A growing understanding of the genetic mutations involved in the syndromes described in this review (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>) is contributing to the identification of more and more cases and the improvement of patient quality of life. Management of these disorders is closely related to control of the associated immune response. Accordingly, many of the syndromes have a specific treatment or benefit from the blockage of certain proinflammatory molecules (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Treatments used to date include TNF inhibitors and IL-1 antagonists. The favorable safety and efficacy profile of IL-1 antagonists, such as anakinra (IL-1 receptor antagonist), rilonacept (dimeric fusion protein), and canakinumab (a fully humanized monoclonal antibody that specifically targets IL-1β), in the treatment of cryopyrin-associated periodic syndromes and deficiency of the interleukin-1 receptor antagonist has prompted the use of these drugs in other autoinflammatory disorders, such as periodic fever disorders and immune dysregulation disorders, including Still disease, Behçet syndrome, and Schnitzler disease. In addition, the fact that the accumulation of metabolic substrates, such as monosodium urate, cholesterol, and glucose, can stimulate the NLRP3 inflammasome due to metabolic stress and the secondary role of IL-1 could justify the use of IL-1 antagonists in highly prevalent diseases, such as gout, diabetes mellitus, and heart disease.<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">33,34</span></a> The use of baricitinib (JAK1/2 inhibitor) in the treatment CANDLE syndrome, for example, is producing promising results.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Ethical Disclosures</span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Protection of humans and animals</span><p id="par0145" class="elsevierStylePara elsevierViewall">The authors declare that no tests were carried out in humans or animals for the purpose of this study.</p></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Confidentiality of data</span><p id="par0150" class="elsevierStylePara elsevierViewall">The authors declare that they have followed their hospital's protocol on the publication of data concerning patients.</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Right to privacy and informed consent</span><p id="par0155" class="elsevierStylePara elsevierViewall">The authors declare that no private patient data appear in this article.</p></span></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0185">Conflicts of Interest</span><p id="par0160" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres888168" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec874140" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres888169" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec874139" "titulo" => "Palabras clave" ] 4 => array:3 [ "identificador" => "sec0005" "titulo" => "Histiocytic and Macrophage Activation Syndromes" "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0010" "titulo" => "Blau Syndrome" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Cutaneous Manifestations" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Associated Clinical Manifestations" ] ] ] 1 => array:3 [ "identificador" => "sec0025" "titulo" => "H Syndrome" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0030" "titulo" => "Cutaneous Manifestations" ] 1 => array:2 [ "identificador" => "sec0035" "titulo" => "Associated Clinical Manifestations" ] ] ] 2 => array:3 [ "identificador" => "sec0040" "titulo" => "Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0045" "titulo" => "Cutaneous Manifestations" ] 1 => array:2 [ "identificador" => "sec0050" "titulo" => "Associated Clinical Manifestations" ] ] ] ] ] 5 => array:3 [ "identificador" => "sec0055" "titulo" => "Vasculopathy Syndromes" "secciones" => array:6 [ 0 => array:3 [ "identificador" => "sec0060" "titulo" => "Type I Interferonopathies" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Aicardi-Goutières Syndrome" ] ] ] 1 => array:3 [ "identificador" => "sec0070" "titulo" => "Cutaneous Manifestations" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0075" "titulo" => "Associated Clinical Manifestations" ] 1 => array:2 [ "identificador" => "sec0080" "titulo" => "Familial Chilblain Lupus" ] ] ] 2 => array:3 [ "identificador" => "sec0085" "titulo" => "Cutaneous Manifestations" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0090" "titulo" => "Associated Clinical Manifestations" ] 1 => array:2 [ "identificador" => "sec0095" "titulo" => "STING-associated Vasculopathy With Onset in Infancy" ] ] ] 3 => array:3 [ "identificador" => "sec0100" "titulo" => "Cutaneous Manifestations" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0105" "titulo" => "Associated Clinical Manifestations" ] 1 => array:2 [ "identificador" => "sec0110" "titulo" => "C1q Deficiency" ] ] ] 4 => array:3 [ "identificador" => "sec0115" "titulo" => "Cutaneous Manifestations" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0120" "titulo" => "Associated Clinical Manifestations" ] ] ] 5 => array:3 [ "identificador" => "sec0125" "titulo" => "ADA2 Deficiency" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0130" "titulo" => "Cutaneous Manifestations" ] 1 => array:2 [ "identificador" => "sec0135" "titulo" => "Associated Clinical Manifestations" ] ] ] ] ] 6 => array:2 [ "identificador" => "sec0140" "titulo" => "Management of Autoinflammatory Syndromes" ] 7 => array:3 [ "identificador" => "sec0145" "titulo" => "Ethical Disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0150" "titulo" => "Protection of humans and animals" ] 1 => array:2 [ "identificador" => "sec0155" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0160" "titulo" => "Right to privacy and informed consent" ] ] ] 8 => array:2 [ "identificador" => "sec0165" "titulo" => "Conflicts of Interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-09-01" "fechaAceptado" => "2016-12-23" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec874140" "palabras" => array:4 [ 0 => "Monogenic autoinflammatory diseases" 1 => "Skin manifestations" 2 => "Classification" 3 => "Histologic diagnosis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec874139" "palabras" => array:4 [ 0 => "Enfermedades autoinflamatorias monogenéticas" 1 => "Manifestaciones cutáneas" 2 => "Clasificación" 3 => "Diagnostico histológico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The discovery of new autoinflammatory syndromes and novel mutations has advanced at breakneck speed in recent years. Part 2 of this review focuses on vasculitis syndromes and the group of histiocytic and macrophage activation syndromes. We also include a table showing the mutations associated with these autoinflammatory syndromes and treatment alternatives.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El descubrimiento de nuevos síndromes autoinflamatorios y nuevas mutaciones está avanzando a una velocidad vertiginosa en los últimos años. La segunda parte de la revisión está centrada en el estudio de los síndromes histiocítico-macrofágicos y de los síndromes vasculopáticos, incluyendo al final del texto una tabla con las alternativas terapéuticas de estos síndromes autoinflamatorios y sus mutaciones genéticas.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Hernández-Ostiz S, Xirotagaros G, Prieto-Torres L, Noguera-Morel L, Torrelo A. Enfermedades autoinflamatorias en dermatología pediátrica. Parte 2: síndromes histiocítico-macrofágicos y síndromes vasculopáticos. Actas Dermosifiliogr. 2017;108:620–629.</p>" ] ] "multimedia" => array:10 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1458 "Ancho" => 933 "Tamanyo" => 247410 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Blau syndrome. Erythematous-brownish papules with a somewhat lichenoid appearance on the arm.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1333 "Ancho" => 1320 "Tamanyo" => 262650 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Blau syndrome. Erythematous-violaceous nodules in both pretibial areas, with a very similar appearance to erythema nodosum.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1237 "Ancho" => 1650 "Tamanyo" => 871501 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Blau syndrome. Noncaseifying granulomas with histiocytes, lymphocytes, eosinophils, and giant multinucleated cells (hematoxylin-eosin, original magnification ×20).</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1237 "Ancho" => 1300 "Tamanyo" => 340934 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">H syndrome. Hyperpigmented, hypertrichotic plaques on the posterior surface of the lower extremities, accompanied by marked sclerosis.</p>" ] ] 4 => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1315 "Ancho" => 1650 "Tamanyo" => 959942 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">H syndrome. Striking fibrosis in the dermis and subcutaneous tissue, with more severe involvement of the subcutis, resulting in progressive obliteration of the fat lobules (hematoxylin-eosin, original magnification ×20).</p>" ] ] 5 => array:7 [ "identificador" => "fig0030" "etiqueta" => "Figure 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 1143 "Ancho" => 1320 "Tamanyo" => 243167 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) syndrome. Edematous erythematous-violaceous annular plaques with raised borders on the trunk, together with anterior residual lesions, including hyperpigmented and ecchymotic macules.</p>" ] ] 6 => array:7 [ "identificador" => "fig0035" "etiqueta" => "Figure 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 1237 "Ancho" => 1650 "Tamanyo" => 648705 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) syndrome. Infiltrate of atypical mononuclear myeloid cells with large, mottled nuclei and scant eosinophilic cytoplasm, accompanied by neutrophils and eosinophils (hematoxylin-eosin, original magnification ×40).</p>" ] ] 7 => array:7 [ "identificador" => "fig0040" "etiqueta" => "Figure 8" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr8.jpeg" "Alto" => 1307 "Ancho" => 1650 "Tamanyo" => 659550 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) syndrome. Positive immunostaining for myeloperoxidase (MPO, original magnification ×20).</p>" ] ] 8 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CANDLE, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature; NSAIDs, nonsteroidal anti-inflammatory drugs; SAVI, STING-associated vasculopathy with onset in infancy; TNF, tumor necrosis factor.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mutation \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Protein \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Treatment \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blau Syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD and sporadic<br><span class="elsevierStyleItalic">NOD2/CARD15</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Nucleotide-binding oligomerization domain–containing protein 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NSAIDs<br>Systemic corticosteroids<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">35</span></a><br>Ciclosporin<br>Methotrexate<br>TNF inhibitors<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">35,36</span></a><br>Thalidomide<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">37</span></a><br>IL-1 antagonists<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">5,6,16,34,38</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H Syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR<br><span class="elsevierStyleItalic">SLC29A3</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">hENT3<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">49</span></a><br> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not established<br>Partial remission with systemic corticosteroids and methotrexate \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CANDLE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PSMB8</span><br><span class="elsevierStyleItalic">PSMB4</span><br><span class="elsevierStyleItalic">PSMB9</span><br><span class="elsevierStyleItalic">PSMA3</span><br><br><span class="elsevierStyleItalic">POMP</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Subunit β5i<br>Subunit β7<br>Subunit β1i<br>Subunit α3<br>Proteasome maturation protein \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NSAIDs<br>Systemic corticosteroids<br>Ciclosporin, methotrexate<br>TNF inhibitors<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">39</span></a><br>IL-1 antagonists<br>IL-6 antagonists<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">17,39</span></a><br>Baricitinib (JAK1/2 inhibitor)<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">40</span></a><br>Tofacitinib<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">17</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aicardi-Goutières \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR<br>(some cases of AD<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">36</span></a>)<br><span class="elsevierStyleItalic">TREX1 RNASEH2</span> (A/B/C)<br><span class="elsevierStyleItalic">SAMHD1</span><br><span class="elsevierStyleItalic">ADAR1</span><br><span class="elsevierStyleItalic">IFIH1</span><br> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">hTREX1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Systemic corticosteroids<br>Azathioprine<br>Intravenous immunoglobulin<br>Type I anti-interferon<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">41</span></a><br>Inverse transcriptase inhibitors<a class="elsevierStyleCrossRefs" href="#bib0450"><span class="elsevierStyleSup">41,42</span></a><br>Mycophenolate mofetil<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">41</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chilblain lupus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD<br>(and some sporadic cases)<br><span class="elsevierStyleItalic">TREX1</span> and <span class="elsevierStyleItalic">SAMHD1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">hTREX1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Topical and systemic corticosteroids<br>Topical immunomodulators<br>Antimalarials<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">33,43,44</span></a><br>Mycophenolate mofetil<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">44</span></a><br>Calcium antagonists<br>Physical warmup<br>Psychotherapy (if anorexia exists)<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">33</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SAVI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD<br><span class="elsevierStyleItalic">TMEM173</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">STING \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">JAK-kinase inhibitors<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">44,45</span></a><br>(tofacitinib, ruxolitinib, baricitinib) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q deficiency \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C1q \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Immunosuppressants<br>Hematopoietic stem cell transplantation<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">46</span></a><br>Fresh frozen plasma<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">47</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Adenosine desaminase 2 deficiency \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR<br><span class="elsevierStyleItalic">CECR1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adenosine desaminase 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Systemic corticosteroids<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">45</span></a><br>Ciclophosphamide<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">45</span></a><br>TNF inhibitors<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">32,48</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1501031.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Genetic Mutations and Treatment Alternatives.</p>" ] ] 9 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: AD, autosomal dominant; AR, autosomal recessive.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Disease \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Heredity \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Genetic mutation \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mutated protein \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Familial Mediterranean fever \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">MEFV</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Pyrin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Mevalonate kinase deficiency (HyperIgD syndrome) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">MVK</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mevalonate kinase \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">TNFRSF1A</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">TNFR (TNF receptor) superfamily IA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Periodic fever with aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Unknown \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PLCG2-associated antibody deficiency and immune dysregulation (PLAID)/Autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PLCG2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Phospholipase CG2 (PLCG2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Familial cold autoinflammatory syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">NLRP3/CIAS1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cryopyrin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Muckle-Wells syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">NLRP3/CIAS1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cryopyrin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Neonatal onset multisystemic inflammatory disorder (NOMID) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">NLRP3/CIAS1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cryopyrin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Deficiency of the interleukin-1 receptor antagonist (DIRA) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">IL-1RN</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Interleukin-1 receptor antagonist \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Deficiency of the interleukin-36 receptor antagonist (DITRA) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">IL-36RN</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Interleukin-36 receptor antagonist \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PSTPIP1/CD2BP1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Proline/serine/threonine phosphatase-interacting protein 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Majeed syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">LPIN2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Lipin 2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blau syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">NOD2/CARD15</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Nucleotide-binding oligomerization domain protein 2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">SLC29A3</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Human equilibrative nucleoside transporter 3 (hENT3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PSMB8</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">i-proteasome β5i subunit \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PSMB4</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Proteasome β7 subunit \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PSMB9</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">i-proteasome β1i subunit \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">PSMA3</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preoteasome α3 subunit \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">POMP</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Proteasome maturation protein \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aicardi–Goutières syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR (rarely AD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">TREX1 (AGS1)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3-prime repair exonuclease 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">RNASEH2 (AGS 2-4)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">RNASEH2 endonuclease complex \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">SAMHD1 (AGS5</span>) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">SAM domain–and HD domain–containing protein 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">ADAR1 (AGS6)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">RNA-specific adenosine deaminase 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">IFIH1 (AGS7)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">interferon-induced helicase c domain-containing protein 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Familial chilblain lupus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">TREX1 (AGS1)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3-prime repair exonuclease 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">SAMHD1 (AGS5</span>) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">SAM domain- and HD domain containing protein 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">STING-associated vasculopathy with onset in infancy (SAVI) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">TMEM173</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Stimulator of interferon genes (STING) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Deficiency of adenosine deaminase 2 (DADA2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">CECR1</span><br> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adenosine deaminase 2 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1501030.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Summary of Main Autoinflammatory Disorders and Mutations.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:49 [ 0 => array:3 [ "identificador" => "bib0250" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NOD2-associated diseases: Bridging innate immunity and autoinflammation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Borzutzky" 1 => "A. Fried" 2 => "J. Chou" 3 => "F.A. Bonilla" 4 => "S. Kim" 5 => "F. Dedeoglu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clim.2009.05.005" "Revista" => array:6 [ "tituloSerie" => "Clin Immunol" "fecha" => "2010" "volumen" => "134" "paginaInicial" => "251" "paginaFinal" => "261" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19467619" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0255" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blau syndrome presenting with ichthyosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G. Masel" 1 => "A. Halbert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1440-0960.2005.00134.x" "Revista" => array:6 [ "tituloSerie" => "Australas J Dermatol" "fecha" => "2005" "volumen" => "46" "paginaInicial" => "29" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15670175" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0260" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical and genetic aspects of Blau syndrome: A 25-year follow-up of one family and a literature review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Punzi" 1 => "A. Furlan" 2 => "M. Podswiadek" 3 => "A. Gava" 4 => "M. Valente" 5 => "M. de Marchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.autrev.2008.07.034" "Revista" => array:6 [ "tituloSerie" => "Autoimmun Rev" "fecha" => "2009" "volumen" => "8" "paginaInicial" => "228" "paginaFinal" => "232" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18718560" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0265" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Stoevesandt" 1 => "H. Morbach" 2 => "T.M. Martin" 3 => "M. Zierhut" 4 => "H. Girschick" 5 => "H. Hamm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1525-1470.2009.01060.x" "Revista" => array:6 [ "tituloSerie" => "Pediatr Dermatol" "fecha" => "2010" "volumen" => "27" "paginaInicial" => "69" "paginaFinal" => "73" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20199415" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0270" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.I. Aróstegui" 1 => "C. Arnal" 2 => "R. Merino" 3 => "C. Modesto" 4 => "M. Antonia Carballo" 5 => "P. Moreno" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.22966" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "3805" "paginaFinal" => "3813" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17968944" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0275" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Deregulated type I IFN response in TREX1-associated familial chilblain lupus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Peschke" 1 => "F. Friebe" 2 => "N. Zimmermann" 3 => "T. Wahlicht" 4 => "T. Schumann" 5 => "M. Achleitner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/jid.2013.496" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2014" "volumen" => "134" "paginaInicial" => "1456" "paginaFinal" => "1459" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24270665" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0280" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Accelerated coronary atherosclerosis and H syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.K. Shankarappa" 1 => "R. Ananthakrishna" 2 => "R.S. Math" 3 => "S.D. Yalagudri" 4 => "S. Karur" 5 => "R. Dwarakaprasad" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "BMJ Case Rep" "fecha" => "2011" "volumen" => "2011" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0285" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The H syndrome: A genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Molho-Pessach" 1 => "Z. Agha" 2 => "S. Aamar" 3 => "B. Glaser" 4 => "V. Doviner" 5 => "N. Hiller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.03.021" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "79" "paginaFinal" => "85" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18410979" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0290" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Proteasome-associated autoinflammatory syndromes: Advances in pathogeneses, clinical presentations, diagnosis, and management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. McDermott" 1 => "J. Jacks" 2 => "M. Kessler" 3 => "P.D. Emanuel" 4 => "L. Gao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ijd.12695" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2015" "volumen" => "54" "paginaInicial" => "121" "paginaFinal" => "129" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25521013" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0295" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Brehm" 1 => "Y. Liu" 2 => "A. Sheikh" 3 => "B. Marrero" 4 => "E. Omoyinmi" 5 => "Q. Zhou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1172/JCI81260" "Revista" => array:6 [ "tituloSerie" => "J Clin Invest" "fecha" => "2015" "volumen" => "125" "paginaInicial" => "4196" "paginaFinal" => "4211" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26524591" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0300" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Torrelo" 1 => "S. Patel" 2 => "I. Colmenero" 3 => "D. Gurbindo" 4 => "F. Lendínez" 5 => "A. Hernández" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.04.046" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2010" "volumen" => "62" "paginaInicial" => "489" "paginaFinal" => "495" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20159315" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0305" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunohistochemistry in dermatopathology: A review of the most commonly used antibodies (part II)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Fuertes" 1 => "C. Santonja" 2 => "H. Kutzner" 3 => "L. Requena" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2012.02.018" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2013" "volumen" => "104" "paginaInicial" => "181" "paginaFinal" => "203" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22995949" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0310" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histiocytoid Sweet syndrome: A dermal infiltration of immature neutrophilic granulocytes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Requena" 1 => "H. Kutzner" 2 => "G. Palmedo" 3 => "M. Pascual" 4 => "J. Fernández-Herrera" 5 => "J. Fraga" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2005" "volumen" => "14" "paginaInicial" => "834" "paginaFinal" => "842" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0315" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Liu" 1 => "Y. Ramot" 2 => "A. Torrelo" 3 => "A.S. Paller" 4 => "N. Si" 5 => "S. Babay" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.33368" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2012" "volumen" => "64" "paginaInicial" => "895" "paginaFinal" => "907" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21953331" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0320" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An unknown autoinflammatory syndrome associated with short stature and dysmorphic features in a young boy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Mégarbané" 1 => "A. Sanders" 2 => "E. Chouery" 3 => "V. Delague" 4 => "M. Medlej-Hashim" 5 => "P-H. Torbey" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2002" "volumen" => "29" "paginaInicial" => "1084" "paginaFinal" => "1087" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12022327" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0325" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Simonini" 1 => "Z. Xu" 2 => "R. Caputo" 3 => "C. de Libero" 4 => "I. Pagnini" 5 => "V. Pascual" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.37776" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2013" "volumen" => "65" "paginaInicial" => "513" "paginaFinal" => "518" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23124805" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0330" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genome-wide DNA hypomethylation and RNA: DNA hybrid accumulation in Aicardi–Goutières syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Y.W. Lim" 1 => "L.A. Sanz" 2 => "X. Xu" 3 => "S.R. Hartono" 4 => "F. Chédin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Elife" "fecha" => "2015" "volumen" => "4" "paginaInicial" => "e08007" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0335" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blueberry muffin rash as the presenting sign of Aicardi-Goutières syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Brisman" 1 => "M. Gonzalez" 2 => "K.D. Morel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1525-1470.2009.00947.x" "Revista" => array:6 [ "tituloSerie" => "Pediatr Dermatol" "fecha" => "2009" "volumen" => "26" "paginaInicial" => "432" "paginaFinal" => "435" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19689519" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0340" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Familial Aicardi-Goutières syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R.C. Dale" 1 => "H. Gornall" 2 => "D. Singh-Grewal" 3 => "M. Alcausin" 4 => "G.I. Rice" 5 => "Y.J. Crow" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Med Genet A" "fecha" => "2010" "volumen" => "152" "paginaInicial" => "938" "paginaFinal" => "942" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0345" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Aicardi-Goutières syndrome: Cutaneous, laboratory, and radiologic findings: A case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Juern" 1 => "A. Robbins" 2 => "S. Galbraith" 3 => "B. Drolet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1525-1470.2009.01055.x" "Revista" => array:6 [ "tituloSerie" => "Pediatr Dermatol" "fecha" => "2010" "volumen" => "27" "paginaInicial" => "82" "paginaFinal" => "85" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20199418" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0350" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Síndrome de Aicardi-Goutières: aportación de dos nuevas observaciones" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Blanco-Barca" 1 => "M.C. Novo" 2 => "A.Á. Moreno" 3 => "A.A. Martín" 4 => "J. Eirís-Puñal" 5 => "M. Castro-Gago" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatr" "fecha" => "2005" "volumen" => "62" "paginaInicial" => "166" "paginaFinal" => "170" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0355" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blue (or purple) toes: Chilblains or chilblain lupus-like lesions are a manifestation of Aicardi-Goutières syndrome and familial chilblain lupus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.S. Prendiville" 1 => "Y.J. Crow" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.05.002" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2009" "volumen" => "61" "paginaInicial" => "727" "paginaFinal" => "728" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19751886" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0360" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic involvement in TREX1-associated familial chilblain lupus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. Günther" 1 => "M. Hillebrand" 2 => "J. Brunk" 3 => "M. Lee-Kirsch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2013.04.020" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2013" "volumen" => "69" "paginaInicial" => "e179" "paginaFinal" => "e181" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24034389" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0365" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chilblain lupus erythematosus—a review of literature" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Hedrich" 1 => "B. Fiebig" 2 => "F. Hauck" 3 => "S. Sallmann" 4 => "G. Hahn" 5 => "C. Pfeiffer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-008-0942-9" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2008" "volumen" => "27" "paginaInicial" => "949" "paginaFinal" => "954" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18543054" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0370" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Abe" 1 => "K. Izawa" 2 => "R. Nishikomori" 3 => "T. Awaya" 4 => "T. Kawai" 5 => "T. Yasumi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kes181" "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2013" "volumen" => "52" "paginaInicial" => "406" "paginaFinal" => "408" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22829693" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0375" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Activated STING in a vascular and pulmonary syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Liu" 1 => "A.A. Jesus" 2 => "B. Marrero" 3 => "D. Yang" 4 => "S.E. Ramsey" 5 => "G.A. Montealegre Sanchez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1312625" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2014" "volumen" => "371" "paginaInicial" => "507" "paginaFinal" => "518" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25029335" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0380" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "STING-associated vasculopathy with onset in infancy--a new interferonopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y.J. Crow" 1 => "J.L. Casanova" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMe1407246" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2014" "volumen" => "371" "paginaInicial" => "568" "paginaFinal" => "571" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25029336" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0385" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Complement in human diseases: Lessons from complement deficiencies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Botto" 1 => "M. Kirschfink" 2 => "P. Macor" 3 => "M.C. Pickering" 4 => "R. Würzner" 5 => "F. Tedesco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.molimm.2009.04.029" "Revista" => array:6 [ "tituloSerie" => "Mol Immunol" "fecha" => "2009" "volumen" => "46" "paginaInicial" => "2774" "paginaFinal" => "2783" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19481265" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0390" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular basis of hereditary C1q deficiency-revisited: Identification of several novel disease-causing mutations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Scheybel" 1 => "L. Skattum" 2 => "S. Hagelberg" 3 => "A. Ahlin" 4 => "B. Schiller" 5 => "S. Berq" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/gene.2011.39" "Revista" => array:6 [ "tituloSerie" => "Genes Immun" "fecha" => "2011" "volumen" => "12" "paginaInicial" => "626" "paginaFinal" => "634" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21654842" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0395" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early-onset stroke and vasculopathy associated with mutations in ADA2" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Q. Zhou" 1 => "D. Yang" 2 => "A.K. Ombrello" 3 => "A.V. Zavialov" 4 => "C. Toro" 5 => "A.V. Zavialov" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1307361" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2014" "volumen" => "370" "paginaInicial" => "911" "paginaFinal" => "920" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24552284" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0400" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutant ADA2 in vasculopathies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.L. Kastner" 1 => "Q. Zhou" 2 => "I. Aksentijevich" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc1405506#SA4" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2014" "volumen" => "371" "paginaInicial" => "480" "paginaFinal" => "481" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25075848" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0405" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Navon Elkan" 1 => "S.B. Pierce" 2 => "R. Segel" 3 => "T. Walsh" 4 => "J. Barash" 5 => "S. Padeh" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1307362" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2014" "volumen" => "370" "paginaInicial" => "921" "paginaFinal" => "931" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24552285" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0410" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-1 blockade in autoinflammatory syndromes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R. Goldbach-Mansky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1146/annurev-med-061512-150641" "Revista" => array:6 [ "tituloSerie" => "Annu Rev Med" "fecha" => "2014" "volumen" => "65" "paginaInicial" => "223" "paginaFinal" => "244" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24422572" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0415" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating inflammation by blocking interleukin-1 in humans" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.A. Dinarello" 1 => "J.W. van der Meer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.smim.2013.10.008" "Revista" => array:6 [ "tituloSerie" => "Semin Immunol" "fecha" => "2013" "volumen" => "25" "paginaInicial" => "469" "paginaFinal" => "484" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24275598" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0420" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biological treatments: New weapons in the management of monogenic autoinflammatory disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Vitale" 1 => "D. Rigante" 2 => "O.M. Lucherini" 3 => "F. Caso" 4 => "I. Muscari" 5 => "F. Magnotti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2013/939847" "Revista" => array:5 [ "tituloSerie" => "Mediators Inflamm" "fecha" => "2013" "volumen" => "2013" "paginaInicial" => "939847" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23970817" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0425" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Milman" 1 => "C.B. Andersen" 2 => "A. Hansen" 3 => "T. van Overeem Hansen" 4 => "F.C. Nielsen" 5 => "H. Fledelius" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1600-0463.2006.apm_522.x" "Revista" => array:6 [ "tituloSerie" => "APMIS" "fecha" => "2006" "volumen" => "114" "paginaInicial" => "912" "paginaFinal" => "919" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17207093" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0430" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: Its possible action and mechanism" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Yasui" 1 => "M. Yashiro" 2 => "M. Tsuge" 3 => "A. Manki" 4 => "K. Takemoto" 5 => "M. Yamamoto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.25035" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2010" "volumen" => "62" "paginaInicial" => "250" "paginaFinal" => "257" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20039400" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0435" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monogenic autoinflammatory diseases: Concept and clinical manifestations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.A. De Jesus" 1 => "R. Goldbach-Mansky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clim.2013.03.016" "Revista" => array:6 [ "tituloSerie" => "Clin Immunol" "fecha" => "2013" "volumen" => "147" "paginaInicial" => "155" "paginaFinal" => "174" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23711932" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0440" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunology in clinic review series; focus on autoinflammatory diseases: Update on monogenic autoinflammatory diseases: The role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R. Goldbach-Mansky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2249.2011.04533.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Immunol" "fecha" => "2012" "volumen" => "167" "paginaInicial" => "391" "paginaFinal" => "404" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22288582" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0445" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Jabbari" 1 => "Z. Dai" 2 => "L. Xing" 3 => "J.E. Cerise" 4 => "Y. Ramot" 5 => "Y. Berkun" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ebiom.2015.02.015" "Revista" => array:6 [ "tituloSerie" => "EBioMedicine" "fecha" => "2015" "volumen" => "2" "paginaInicial" => "351" "paginaFinal" => "355" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26137574" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0450" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapies in Aicardi-Goutières syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Y.J. Crow" 1 => "A. Vanderver" 2 => "S. Orcesi" 3 => "T.W. Kuijpers" 4 => "G.I. Rice" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/cei.12115" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Immunol" "fecha" => "2014" "volumen" => "175" "paginaInicial" => "1" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23607857" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0455" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Type I interferonopathies: A novel set of inborn errors of immunity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Y.J. Crow" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1749-6632.2011.06220.x" "Revista" => array:6 [ "tituloSerie" => "Ann N Y Acad Sci" "fecha" => "2011" "volumen" => "1238" "paginaInicial" => "91" "paginaFinal" => "98" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22129056" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0460" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Docetaxel-induced relapse of subacute cutaneous lupus erythematosus and chilblain lupus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Lebeau" 1 => "S. També" 2 => "M.A. Sallam" 3 => "A. Alhowaish" 4 => "C. Tschanz" 5 => "I. Masouyé" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ddg.12142" "Revista" => array:6 [ "tituloSerie" => "J Dtsch Dermatol Ges" "fecha" => "2013" "volumen" => "11" "paginaInicial" => "871" "paginaFinal" => "874" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23848065" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0465" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The STING pathway and regulation of innate immune signaling in response to DNA pathogens" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H. Ishikawa" 1 => "G.N. Barber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00018-010-0605-2" "Revista" => array:6 [ "tituloSerie" => "Cell Mol Life Sci" "fecha" => "2011" "volumen" => "68" "paginaInicial" => "1157" "paginaFinal" => "1165" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21161320" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0470" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.N. Hawkins" 1 => "H.J. Lachmann" 2 => "E. Aganna" 3 => "M.F. McDermott" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20033" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2004" "volumen" => "50" "paginaInicial" => "607" "paginaFinal" => "612" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14872505" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0475" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "P. Mehta" 1 => "P.J. Norsworthy" 2 => "A.E. Hall" 3 => "S.J. Kelly" 4 => "M.J. Walport" 5 => "M. Botto" 6 => "M.C. Pickering" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kep387" "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2010" "volumen" => "49" "paginaInicial" => "823" "paginaFinal" => "824" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19965977" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0480" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P.D. Arkwright" 1 => "P. Riley" 2 => "S.M. Hughes" 3 => "H. Alachkar" 4 => "R.F. Wynn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2013.07.035" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2014" "volumen" => "133" "paginaInicial" => "265" "paginaFinal" => "267" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24035158" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0485" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An autoinflammatory disease due to homozygous deletion of the IL1RN locus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Reddy" 1 => "S. Jia" 2 => "R. Geoffrey" 3 => "R. Lorier" 4 => "M. Suchi" 5 => "U. Broeckel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0809568" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "360" "paginaInicial" => "2438" "paginaFinal" => "2444" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19494219" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0490" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The H syndrome: Two novel mutations affecting the same amino acid residue of hENT3" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Molho-Pessach" 1 => "J. Suarez" 2 => "C. Perrin" 3 => "C. Chiaverini" 4 => "V. Doviner" 5 => "E. Tristan-Clavijo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jdermsci.2009.09.011" "Revista" => array:6 [ "tituloSerie" => "J Dermatol Sci" "fecha" => "2010" "volumen" => "57" "paginaInicial" => "59" "paginaFinal" => "61" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19889517" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010800000007/v2_201708291348/S1578219017302147/v2_201708291348/en/main.assets" "Apartado" => array:4 [ "identificador" => "6177" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010800000007/v2_201708291348/S1578219017302147/v2_201708291348/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302147?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 19 | 17 | 36 |
2024 Octubre | 96 | 41 | 137 |
2024 Septiembre | 104 | 23 | 127 |
2024 Agosto | 153 | 72 | 225 |
2024 Julio | 114 | 38 | 152 |
2024 Junio | 155 | 66 | 221 |
2024 Mayo | 100 | 53 | 153 |
2024 Abril | 119 | 42 | 161 |
2024 Marzo | 91 | 39 | 130 |
2024 Febrero | 102 | 60 | 162 |
2024 Enero | 88 | 44 | 132 |
2023 Diciembre | 93 | 34 | 127 |
2023 Noviembre | 85 | 47 | 132 |
2023 Octubre | 103 | 53 | 156 |
2023 Septiembre | 110 | 48 | 158 |
2023 Agosto | 83 | 33 | 116 |
2023 Julio | 110 | 45 | 155 |
2023 Junio | 90 | 33 | 123 |
2023 Mayo | 110 | 33 | 143 |
2023 Abril | 101 | 44 | 145 |
2023 Marzo | 105 | 70 | 175 |
2023 Febrero | 98 | 44 | 142 |
2023 Enero | 83 | 71 | 154 |
2022 Diciembre | 74 | 57 | 131 |
2022 Noviembre | 60 | 47 | 107 |
2022 Octubre | 46 | 21 | 67 |
2022 Septiembre | 40 | 49 | 89 |
2022 Agosto | 48 | 51 | 99 |
2022 Julio | 58 | 51 | 109 |
2022 Junio | 45 | 39 | 84 |
2022 Mayo | 76 | 53 | 129 |
2022 Abril | 83 | 54 | 137 |
2022 Marzo | 113 | 76 | 189 |
2022 Febrero | 78 | 65 | 143 |
2022 Enero | 82 | 71 | 153 |
2021 Diciembre | 69 | 72 | 141 |
2021 Noviembre | 61 | 58 | 119 |
2021 Octubre | 49 | 65 | 114 |
2021 Septiembre | 56 | 52 | 108 |
2021 Agosto | 45 | 49 | 94 |
2021 Julio | 52 | 51 | 103 |
2021 Junio | 42 | 50 | 92 |
2021 Mayo | 52 | 71 | 123 |
2021 Abril | 137 | 93 | 230 |
2021 Marzo | 107 | 65 | 172 |
2021 Febrero | 78 | 62 | 140 |
2021 Enero | 78 | 46 | 124 |
2020 Diciembre | 43 | 41 | 84 |
2020 Noviembre | 62 | 34 | 96 |
2020 Octubre | 47 | 20 | 67 |
2020 Septiembre | 49 | 26 | 75 |
2020 Agosto | 44 | 36 | 80 |
2020 Julio | 34 | 24 | 58 |
2020 Junio | 46 | 38 | 84 |
2020 Mayo | 24 | 14 | 38 |
2020 Abril | 26 | 19 | 45 |
2020 Marzo | 32 | 20 | 52 |
2020 Febrero | 4 | 2 | 6 |
2019 Diciembre | 4 | 0 | 4 |
2019 Septiembre | 4 | 0 | 4 |
2019 Agosto | 1 | 0 | 1 |
2019 Julio | 1 | 0 | 1 |
2019 Junio | 1 | 0 | 1 |
2019 Mayo | 3 | 0 | 3 |
2019 Marzo | 2 | 0 | 2 |
2019 Febrero | 5 | 0 | 5 |
2019 Enero | 1 | 0 | 1 |
2018 Diciembre | 4 | 0 | 4 |
2018 Noviembre | 2 | 0 | 2 |
2018 Octubre | 4 | 0 | 4 |
2018 Septiembre | 4 | 0 | 4 |
2018 Mayo | 0 | 1 | 1 |
2018 Febrero | 40 | 4 | 44 |
2018 Enero | 83 | 13 | 96 |
2017 Diciembre | 68 | 13 | 81 |
2017 Noviembre | 60 | 7 | 67 |
2017 Octubre | 78 | 24 | 102 |
2017 Septiembre | 238 | 39 | 277 |
2017 Agosto | 137 | 36 | 173 |
2017 Julio | 4 | 22 | 26 |